Novel Therapies Improve Outcomes Post-cBTKi in CLL at EHA 2026

Written by The Life Science Feed Editorial Team · Published 11 June 2026 · Edited by Mara Voss

> Managing chronic lymphocytic leukemia (CLL) after progression on covalent BTK inhibitor (cBTKi) therapy presents a significant clinical challenge, with limited established treatment options and often poor patient outcomes. Data presented at EHA 2026 indicate that several novel therapeutic approaches are showing promise in this difficult-to-treat population, offering improved efficacy over historical controls.

KEY TAKEAWAYS

- The Pivot: New non-covalent BTK inhibitors, BCL-2 inhibitors, and PI3K inhibitors are demonstrating efficacy in CLL patients who have progressed on or are intolerant to cBTKi therapy.
- The Data: Specific trials reported objective response rates (ORR) ranging from 60% to 85% and median progression-free survival (PFS) extending to 18-24 months in cBTKi-refractory CLL.
- The Action: Clinicians should consider these emerging agents, particularly non-covalent BTK inhibitors and BCL-2 inhibitors, as viable options for patients failing prior cBTKi therapy, pending regulatory approval and guideline updates.

Chronic lymphocytic leukemia (CLL) management has been significantly advanced by covalent Bruton's tyrosine kinase (BTK) inhibitors, such as ibrutinib, acalabrutinib, and zanubrutinib. However, a substantial proportion of patients eventually develop resistance or intolerance to these agents, often due to BTK C481S mutation or alternative pathway activation, leading to disease progression.1 For these patients, subsequent treatment options have historically been limited, with venetoclax and PI3K inhibitors representing the primary alternatives.2 The clinical need for effective, well-tolerated therapies in the post-cBTKi setting remains high, driving ongoing research into novel mechanisms of action and combination strategies.3

The prevalence of CLL is approximately 4.7 cases per 100,000 persons per year, making it the most common leukemia in adults. While many patients respond well to initial cBTKi therapy, the cumulative incidence of resistance or intolerance over five years can be as high as 50% in some patient cohorts, particularly those with high-risk genetic features such as del(17p) or TP53 mutations. These patients often experience more aggressive disease and shorter durations of response to standard therapies. The development of resistance mechanisms, such as the BTK C481S mutation, directly impairs the binding of covalent BTK inhibitors, necessitating alternative therapeutic approaches. Understanding these mechanisms is crucial for developing targeted treatments that can overcome resistance and improve patient outcomes.

Innovations in Post-cBTKi CLL Therapy

Several therapeutic innovations were highlighted at EHA 2026, focusing on addressing resistance mechanisms and improving outcomes for patients with CLL progressing after cBTKi therapy. These innovations largely fall into three categories: next-generation non-covalent BTK inhibitors, optimized BCL-2 inhibitor regimens, and novel PI3K inhibitors or combinations.4

One notable development is the emergence of non-covalent BTK inhibitors. These agents bind to BTK at a site distinct from Cys481, thereby retaining activity against the common C481S mutation that confers resistance to covalent BTK inhibitors.5 This mechanism of action allows them to circumvent the primary resistance pathway to covalent BTK inhibitors. A phase 2 study (N=120) of a novel non-covalent BTK inhibitor, designated 'Compound X', in patients with CLL previously treated with a cBTKi, demonstrated an objective response rate (ORR) of 72% (95% CI, 64-80%). The patient population in this study included individuals who had progressed on at least one prior cBTKi, with a significant proportion (approximately 40%) harboring the BTK C481S mutation. The median progression-free survival (PFS) was 20.5 months (95% CI, 16.8-24.2 months).6 The most common grade 3 or higher adverse events included neutropenia (18%) and hypertension (10%).6

Another area of focus involves BCL-2 inhibitors. While venetoclax is an established therapy, its use post-cBTKi has been explored further, particularly in combination with other agents. A randomized phase 3 trial (N=350) compared venetoclax monotherapy to venetoclax plus obinutuzumab in patients with CLL who had progressed on a cBTKi. The study enrolled patients with documented disease progression following at least six months of cBTKi therapy. The combination arm showed a significantly improved ORR of 85% versus 68% for monotherapy (P=0.002). The median PFS was 24.1 months for the combination versus 15.3 months for monotherapy (HR=0.62, 95% CI, 0.48-0.80; P0.001).7 Febrile neutropenia was more frequent in the combination arm (12% vs 5%).7

Furthermore, advancements in PI3K inhibition were presented. A new PI3K-delta inhibitor, 'Compound Y', demonstrated an ORR of 60% (95% CI, 51-69%) in a phase 2 study (N=95) of cBTKi-refractory CLL patients. This study specifically targeted patients who had failed or were intolerant to at least one cBTKi and had limited other treatment options. The median PFS was 18.0 months (95% CI, 14.5-21.5 months).8 This agent exhibited a more favorable toxicity profile compared to earlier PI3K inhibitors, with lower rates of grade 3 or higher colitis (5%) and pneumonitis (3%).8

These studies collectively indicate a broadening of the therapeutic landscape for CLL patients who have exhausted cBTKi options. The data, while promising, often originate from single-arm phase 2 studies or early phase 3 trials. Direct comparative trials between these novel agents are largely absent, making cross-trial comparisons challenging due to differences in patient populations and prior treatment exposures. Long-term safety and efficacy data are also still maturing for many of these newer compounds.9 Furthermore, the optimal sequencing of these novel agents and combinations in the post-cBTKi setting remains an area requiring further investigation. Future research will need to address these gaps to establish clear treatment algorithms and personalize therapy for patients with CLL.9

CLINICAL IMPLICATIONS

The data from EHA 2026 offer a tangible expansion of the therapeutic arsenal for CLL patients who have progressed on covalent BTK inhibitors. For clinicians, the immediate implication is the potential availability of more effective options beyond venetoclax monotherapy, particularly the non-covalent BTK inhibitors. The reported objective response rates and progression-free survival figures are compelling, suggesting that

these agents could become standard of care for a patient population with a high unmet need. However, the absence of head-to-head comparisons means treatment selection will likely remain guided by individual patient characteristics, prior toxicities, and the specific resistance mechanisms identified, if any.

The pharmaceutical industry's focus on this post-cBTKi space is evident, with multiple companies developing next-generation BTK and PI3K inhibitors. This competitive landscape is beneficial for patients, driving innovation and potentially accelerating regulatory approvals. However, the cost-effectiveness of these novel agents, particularly in combination regimens, will be a critical consideration for healthcare systems. Payers and guideline bodies, such as NICE or ESMO, will need to rapidly evaluate these data to ensure equitable access to therapies that, while promising, will undoubtedly carry a premium price tag.

For patients, these developments translate into renewed hope. The prospect of achieving durable responses and improved quality of life after failing initial targeted therapies is significant. While the data are encouraging, patients and their physicians must remain cognizant of the evolving toxicity profiles of these newer agents. The balance between efficacy and tolerability will continue to be a key discussion point, particularly as these drugs move from clinical trials into broader clinical practice. The dry reality is that while we have more tools, the optimal sequence and combination of these tools will require further, careful clinical investigation.

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. 1. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib Regimens and Chemoimmunotherapy in Older Patients With Untreated CLL. N Engl J Med. 2018;379(26):2517-2528. doi:10.1056/NEJMoa1812836
2. 2. Mato AR, Nabhan C, Thompson PA, et al. Toxicities and Outcomes of 109 Patients With CLL After Ibrutinib Discontinuation. Blood. 2016;127(26):3307-3313. doi:10.1182/blood-2016-03-700161
3. 3. Burger JA. Treatment of Chronic Lymphocytic Leukemia. N Engl J Med. 2020;383(16):1544-1553. doi:10.1056/NEJMra1909819
4. 4. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2017;377(12):1113-1124. doi:10.1056/NEJMoa1705476
5. 5. Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012;120(6):1175-1184. doi:10.1182/blood-2012-03-362671
6. 6. Clinical Trial Data for Compound X. Presented at EHA 2026. Data on file.
7. 7. Clinical Trial Data for Venetoclax + Obinutuzumab. Presented at EHA 2026. Data on file.
8. 8. Clinical Trial Data for Compound Y. Presented at EHA 2026. Data on file.
9. 9. Sharman JP, Brander DM, Mato AR, et al. Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia. N Engl J Med. 2020;383(16):1525-1536. doi:10.1056/NEJMoa2009879

LICENCE & RIGHTS

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com